Abstract:
There are disclosed chemically active poly(ethylene glycols) and other hydrophilic polymers that are suitable for coupling to pharmaceutically or diagnostically active agents such as peptides, oligonucleotides, proteins or non- peptide molecules. The compounds are represented by the formula Poly-(X-NH-CO-A) n wherein: Poly is a hydrophilic polymer having a molecular weight of from about 300 to 100000 Daltons; A together with -NH-CO- forms a reactive group; X is a spacer moiety or a bond; n is an integer comprised between 1 and 50. The active agents of interest which may be conjugated to the disclosed compounds may be selected from hemoglobin, insulin, urokinase, alpha- interferon, G-CSF, hGH, asparaginase, adenosine deaminase, superoxide dismutase and catalase.
Abstract translation:公开了化学活性聚(乙二醇)和其它亲水性聚合物,其适于与药学或诊断活性剂如肽,寡核苷酸,蛋白质或非肽分子偶联。 所述化合物由下式表示:Poly-(X-NH-CO-A)n N n其中:Poly是分子量为约300至100000道尔顿的亲水性聚合物; A与-NH-CO-一起形成反应性基团; X是间隔部分或键; 可以与所公开的化合物缀合的感兴趣的活性剂可以选自血红蛋白,胰岛素,尿激酶,α-干扰素,G-CSF,hGH,天冬酰胺酶,腺苷脱氨酶,超氧化物歧化酶 和过氧化氢酶。
Abstract:
Novel site-specific mono-conjugates of Granulocyte Colony Stimulating Factor (G-CSF) are hereby described, with analogues and derivatives thereof, which stimulate proliferation and differentiation of progenitor cells to mature neutrophiles. These conjugates have been obtained using transglutaminase to covalently and site-specifically bind a hydrophilic, non-immunogenic polymer to a single glutamine residue of the human G-CSF native sequence and analogues thereof. These novel site-specific mono-conjugated derivatives are recommended for therapeutic use since they are stable in solution and exhibit significant biological activity in vitro and a longer bloodstream half-life, as compared to the non-conjugated protein, with a consequent prolonged pharmacological activit y.
Abstract:
The present invention is related to glucagon-like peptide- 1 (GLP-1) and analogues insulinotropic peptides, monoconjugated to biocompatible polymeric molecules by enzymatic direct and site-specific transglutamination reaction as well as their pharmaceutical formulations and delivery systems for therapeutical application in dismetabolic pathologies such as type 2 diabetes.